comparemela.com

Latest Breaking News On - Geoexplorers ltd - Page 1 : comparemela.com

Investegate |Kavango Resources Announcements | Kavango Resources: Kalahari Copper Belt

Investegate |Kavango Resources Announcements | Kavango Resources: Kalahari Copper Belt
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

Kavango Resources PLC says extensive copper/silver targets indentified on LVR joint venture

Kavango has the right to acquire a 90% interest in the licences Kavango Resources PLC (LON:KAV) said extensive copper/silver targets have been identified on two prospecting licences at the LVR joint venture project in the Kalahari Copper Belt. The licences - 082/2018 and 083/2018 - are jointly held with LVR GeoExplorers Ltd. Kavango, which has the right to acquire a 90% interest in the licences through staged exploration spending commitments, said its stake in the LVR project is 25% now that Stage 1 of the LVR farm-in is complete. The targets were detected as a result of recent Airborne EM (AEM) surveys flown over the project.  

Kavango Resources PLC (LSE:KAV) | RNS | Kavango Resources - KCB update - Cu-Ag targets identified on LVR JV

Proactive headlines: Jubilee Metals Group PLC, Faron Pharmaceuticals Oy, Redx Pharma PLC…

Proactive headlines: Jubilee Metals, Faron Pharmaceuticals, Redx Pharma… A look at some of the main headlines from the Proactive newswire Jubilee Metals Group PLC (LON:JLP) said it entered into long-term PGM (platinum group metals) feed supply agreement with a chrome mining customer, signalling Jubilee s PGM expansion into the Eastern Limb of the Bushveld Complex in South Africa. Faron Pharmaceuticals Oy (LON:FARN, First North:FARON) said research has been published supporting the immunotherapeutic blockade of Clever-1 to activate anti-tumour immune responses in advanced cancer patients. Redx Pharma PLC (AIM:REDX) said its second wholly-owned molecule has now entered the clinic. Candidate RXC007, which is being developed to treat fibrosis, will be administered to healthy volunteers to assess its safety and tolerability and also the way it interacts with the body.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.